We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Novel Antibody Tests Reveal Complexity of Immune Response to COVID-19

By LabMedica International staff writers
Posted on 11 Feb 2021
Researchers have developed two assays that reveal the ability of antibodies to target SARS-CoV-2, particularly the spike protein essential for viral entry into cells, may help determine disease susceptibility and progression in patients.

The interaction of SARS-CoV-2, the novel coronavirus causing the global COVID-19 pandemic, and the human immune system is the focus of intensive research at The Jackson Laboratory (Bar Harbor, ME USA), leading to the development of two assays. More...
The first one is a highly sensitive and specific antibody test to determine the magnitude of total and different types of antibodies against the virus surface (Spike) and nuclear (nucleocapsid) proteins, while the second determines how well anti-SARS-CoV-2 antibodies are able to neutralize binding with ACE-2, the human receptor for the virus. In the latter assay, the team used a non-infectious pseudo-virus with the SARS-CoV-2 spike protein on the external membrane, meaning the assay does not require a BSL-3-level biosecurity facility yet detects the presence of neutralizing antibodies with extremely high sensitivity and specificity.

In their study, the researchers have shown that the assay is able to detect neutralizing antibody in patient plasma even at high dilutions, up to a 100 thousand-fold. Working with samples from 115 subjects with confirmed SARS-Cov-2 infection as well as healthy controls (56 subjects from year-old frozen samples to ensure non-infection), the team was able to determine accurate antibody levels in every patient. The assay is also sufficiently sensitive to distinguish background levels of antibody in control samples which may have been from anti-SARS-CoV-2 antibodies in patient plasma. In addition, the antibody assay provides the ability to identify antibody isotopes and assess the ratio of IgA, IgG and IgM present in each sample.

In the analysis of the patient antibody levels and neutralization, the team had several key findings. First, samples from patients with severe disease - in the ICU or deceased - had almost 100-fold higher neutralizing antibody levels than those with cases mild enough not to require hospitalization. Why, then, did they get so sick? Could extremely high levels of antibody even be harmful? And how would that influence the use of convalescent plasma as a therapy in severely ill patients who already have high antibody levels? Second, most convalescent plasma samples obtained to treat severe patients had much lower antibody levels, suggesting plasma therapy of hospitalized patients would not benefit them. Indeed, recent findings, including those using synthetic antibodies, strongly support this result. Third, there was big difference - almost a thousand-fold - in the level of neutralizing capacity of antibodies among different subjects.

The results suggest that some individuals with low neutralizing antibodies may be protected for a shorter period of time than others, an important finding given the recent emergence of antibody-evading mutant viruses in South Africa and Brazil. Interestingly, some of patient plasma was also able to effectively neutralize the original SARS virus, and there was no particular correlation with the levels of neutralization with SARS-Cov-2. This could be due to the fact that these two viruses have similar Spike surface protein structures and both use ACE2 as a receptor to enter into cells. It remains to be determined whether antibodies that can block both viruses can be more effective in neutralizing SARS-Cov-2.

The researchers will continue to use these assays to follow some subjects six months to a year post-infection, in both adults and children as well as post-vaccination. These studies will be critical for understanding the precise relationship between antibody levels and protection from reinfection, as well as protection acquired through vaccination. They also suggest the use of therapies that target excessive antibodies generated during the severe disease-causing immune pathology.

Related Links:
The Jackson Laboratory


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.